New catheter aims to boost radiation to liver tumors while sparing healthy tissue

NCT ID NCT07444645

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special catheter called TriNav can deliver more radiation beads (Y90 microspheres) to liver tumors while reducing exposure to healthy liver tissue. Twenty adults with unresectable liver tumors will receive the standard radioembolization procedure using both the TriNav and a standard catheter, and doctors will compare CT scans to see which delivers a better tumor-to-normal liver ratio. The goal is to see if the TriNav device can improve treatment precision without increasing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Y90 microsphere therapy (radioembolization)
What this could lead to
If successful, this could show that using the TriNav catheter delivers more radiation to liver tumors while sparing healthy liver tissue, potentially improving treatment outcomes.
What could go wrong
This is a very small, early-phase study (20 people) that only measures imaging changes, not survival or cure. The device may not work better than standard catheters, and there is a risk of side effects from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.